EOLS
Evolus, Inc.
$7.37
+0.01
(+0.14%)
Mkt Cap
486.13M
Volume
447,803
52W Range
3.86-9.31
Sector
Healthcare
Beta
1.34
EPS (TTM)
-0.52 USD
P/E Ratio
-8.31
Revenue (TTM)
316.49M USD
Rev Growth (5Y)
+39.4%
EPS Growth (5Y)
N/A
Company Description
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 297.18M | 266.27M | 202.09M | 148.62M | 99.67M | 56.54M | 34.92M | 0 | 0 | 0 | 0 |
| Net Income | (51.64M) | (50.42M) | (61.69M) | (74.41M) | (46.81M) | (163.01M) | (90.03M) | (46.87M) | (4.48M) | (20.07M) | (31.11M) |
| EPS | -0.80 | -0.81 | -1.08 | -1.33 | -0.94 | -4.83 | -3.19 | -1.92 | -0.19 | -1.08 | -1.67 |
| Free Cash Flow | (50.72M) | (19.47M) | (35.63M) | (87.85M) | (34.36M) | (61.01M) | (97.95M) | (25.68M) | (13.04M) | (13.27M) | (36.38M) |
| FCF / Share | -0.79 | -0.31 | -0.63 | -1.57 | -0.69 | -1.81 | -3.47 | -1.05 | -0.55 | -0.71 | -1.96 |
| Operating CF | (42.27M) | (18.00M) | (34.01M) | (84.91M) | (33.39M) | (57.87M) | (93.38M) | (25.67M) | (13.04M) | (13.27M) | (36.38M) |
| Total Assets | 225.87M | 232.57M | 189.00M | 177.98M | 257.48M | 209.07M | 240.44M | 171.84M | 152.23M | 77.50M | 81.30M |
| Total Debt | 155.00M | 129.98M | 126.55M | 74.42M | 74.74M | 138.32M | 96.55M | 16.90M | 211.33M | 59.76M | 46.17M |
| Cash & Equiv | 53.83M | 86.95M | 62.84M | 53.92M | 146.26M | 102.56M | 109.89M | 93.16M | 0 | 0 | 4.00M |
| Book Value | (23.11M) | 5.52M | (20.69M) | 18.50M | 81.88M | (72.96M) | 79.46M | (123.03M) | (75.54M) | (7.11M) | 12.00M |
| Return on Equity | N/A | -9.13 | N/A | -4.02 | -0.57 | N/A | -1.13 | N/A | N/A | N/A | -2.59 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 84.08M | 73.14M | 90.30M | 68.97M | 69.39M | 68.52M | 78.95M | 61.09M | 66.91M | 59.33M | 61.00M | 50.02M |
| Net Income | (8.05M) | (10.67M) | 130,000 | (15.74M) | (17.14M) | (18.89M) | (6.79M) | (19.17M) | (11.35M) | (13.11M) | (11.83M) | (16.92M) |
| EPS | -0.12 | -0.16 | 0.00 | -0.24 | -0.27 | -0.30 | -0.11 | -0.30 | -0.18 | -0.22 | -0.21 | -0.30 |
| Free Cash Flow | (2.36M) | (11.64M) | 10.66M | (16.83M) | (27.06M) | (17.49M) | 3.45M | (7.13M) | (7.72M) | (11.41M) | 452,000 | (1.46M) |
| FCF / Share | -0.04 | -0.18 | 0.17 | -0.26 | -0.42 | -0.27 | 0.06 | -0.11 | -0.12 | -0.19 | 0.01 | -0.03 |
| Operating CF | (3.59M) | (9.95M) | 12.83M | (14.67M) | (24.79M) | (15.63M) | 4.81M | (5.72M) | (6.47M) | (10.62M) | 813,000 | (924,000) |
| Total Assets | 248.02M | 220.65M | 225.87M | 219.00M | 228.80M | 213.36M | 232.57M | 229.61M | 233.77M | 226.18M | 189.00M | 167.97M |
| Total Debt | 164.80M | 164.90M | 155.00M | 154.89M | 154.91M | 130.20M | 129.98M | 129.88M | 126.75M | 126.65M | 126.55M | 101.44M |
| Cash & Equiv | 45.17M | 49.79M | 53.83M | 43.52M | 61.74M | 67.89M | 86.95M | 85.03M | 93.67M | 96.96M | 62.84M | 38.69M |
| Book Value | (30.90M) | (28.78M) | (23.11M) | (28.76M) | (18.65M) | (6.60M) | 5.52M | 5.89M | 19.31M | 18.44M | (20.69M) | (19.37M) |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | -1.23 | -3.25 | -0.59 | -0.71 | N/A | N/A |
EOLS News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law
EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug
Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
BlackRock Inc. Makes New Investment in Evolus, Inc. $EOLS
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture